Markus Aebi
Corporate Officer/Principal bei Institute of Microbiology
Aktive Positionen von Markus Aebi
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Institute of Microbiology | Corporate Officer/Principal | 22.09.2011 | - |
Karriereverlauf von Markus Aebi
Ehemalige bekannte Positionen von Markus Aebi
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Swiss National Science Foundation | Corporate Officer/Principal | 01.01.1994 | 01.01.1994 |
Malcisbo AG
 Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2010 | - |
| Gründer | 01.05.2010 | - |
Ausbildung von Markus Aebi
| University of Zurich | Doctorate Degree |
| California Institute of Technology | Undergraduate Degree |
Statistik
International
| Schweiz | 4 |
| Bulgarien | 2 |
| Vereinigte Staaten | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sektoral
| Consumer Services | 4 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Malcisbo AG
Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Health Technology |
| Swiss National Science Foundation |
- Börse
- Insiders
- Markus Aebi
- Erfahrung
